Genenta Science, a biotechnology company focused on developing gene therapies for cancer, saw a significant increase in its stock price following a direct offering of $15 million.
The company announced the offering on Monday, stating that it had entered into definitive agreements with several institutional investors to purchase 1.5 million shares of its common stock at a price of $10 per share. This represents a 10% discount to the closing price of Genenta’s stock on Friday.
As a result of this offering, Genenta’s stock price jumped by over 20% on Monday, reaching a high of $12.50 per share. This surge in stock price reflects the market’s confidence in the company’s potential for success in the field of gene therapy.
Genenta’s lead product candidate, GEN-1, is currently in Phase I/II clinical trials for the treatment of ovarian cancer. The company also has a pipeline of other gene therapy candidates targeting various types of cancer, including multiple myeloma and glioblastoma.
The proceeds from this direct offering will be used to fund the ongoing clinical trials for GEN-1 and to advance the development of other gene therapy candidates in Genenta’s pipeline. The company also plans to use the funds for general corporate purposes.
Genenta’s CEO, Pierluigi Paracchi, expressed his excitement about the direct offering, stating that it will provide the necessary resources to continue the company’s mission of developing innovative gene therapies for cancer patients.
In addition to the direct offering, Genenta also announced that it has entered into a securities purchase agreement with certain investors for the sale of an additional 1.5 million shares of its common stock at a price of $10 per share. This agreement is expected to close on or around June 16, 2021, subject to customary closing conditions.
Overall, the direct offering and securities purchase agreement demonstrate the strong interest and support from institutional investors in Genenta’s potential to revolutionize cancer treatment through gene therapy. With the additional funding, the company is well-positioned to continue its promising research and development efforts.
